Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated <i>MGMT</i> promoter

2022468 citationsJournal Articlebronze Open Access

Authors

Michael Lim · Stanford University

Michael Weller · University of Zurich

Ahmed Idbaïh · Centre National de la Recherche Scientifique

Joachim P. Steinbach · Goethe University Frankfurt

Gaetano Finocchiaro

Raju R. Raval · Translational Therapeutics (United States)

George Ansstas · Washington University in St. Louis

Abstract

NIVO added to RT + TMZ did not improve survival in patients with newly diagnosed glioblastoma with methylated or indeterminate MGMT promoter. No new safety signals were observed.

Topics & Keywords

Glioma Diagnosis and Treatment Brain Metastases and Treatment Cancer Immunotherapy and Biomarkers

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Neuro-Oncology

Volume 24, Issue 11, pp. 1935-1949

DOI: 10.1093/neuonc/noac116

Field-Weighted Citation Impact: 66.24